Discovery Portfolio
- Phenotypic Hit-to-Lead University of Illinois, TB Alliance
- M. tuberculosis Protein Kinase Inhibitors Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles Vertex Pharmaceuticals, Incorporated
- Fungal metabolites Mycosynthetix, University of Illinois at Chicago
- Actinomycete metabolites University of Illinois at Chicago, Myongji University
- DNA metabolism Novel structural class AstraZeneca R and D Bangalore
- Phenotypic hit to lead Multiple novel structural classes Lilly TB Drug Discovery Initiative
- Novel hit-lead programs Novel structural class Lilly TB Drug Discovery Initative
- Phenotype Hit-to-Lead Novel structural classes AstraZeneca R and D Bangalore
- Combinatorial Biosynthetic Compounds Shaw Environmental and University of Illinois at Chicago
- Folate Biosynthesis Inhibitors AstraZeneca, TB Alliance
- Phenotypic Hit-to-Lead GlaxoSmithKline, TB Alliance
- Malate Synthase Inhibitors GlaxoSmithKline , Texas A&M University, TB Alliance
- Menaquinone Synthase Inhibitors Colorado State University, TB Alliance
- Inhibitors of Mycobacterium Tuberculosis Energy Metabolism Various Classes UPenn and TB Alliance
- Inhibitors of isoprenoid biosynthesis Lilly TB Drug Discovery Initiative
- Protein Splicing Inhibitors Boston Biomedical Research Institute
- Diarylquinolines Diarylquinoline TB Alliance, University of Auckland, Tibotec
- Riminophenazines Riminophenazines antibiotic TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois
- InhA Inhibitors Novel structural class GlaxoSmithKline, TB Alliance
- LeuRS inhibitors Oxaboroles Anacor Pharmaceuticals
- Mycobacterial Gyrase Inhibitors Novel structural class TB Alliance, GlaxoSmithKline
- Pyrazinamide Analogs Pyrazinamide/nicotinamide analogs TB Alliance/Yonsei University
- TL1 Inhibitors Capuramycins Sequella
- MTopo Novel structural class AstraZeneca R and D Bangalore
- GyrB Inhibitors AstraZeneca , TB Alliance
- SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis Inorganic Compounds FAPESP/Brazil
- Spectinamides Spectinomycin analogs St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix